Long-term hepatitis E viral load kinetics in an immunocompromised patient treated with ribavirin.

Abstract

Hepatitis E virus (HEV) can cause chronic infections in immunocompromised hosts. Viral kinetics in plasma and stools are poorly understood, particularly during antiviral treatment. Prolonged faecal shedding may be a concern for transmission. We describe HEV kinetics in an immunocompromised patient with prolonged faecal shedding despite undetectable viraemia on ribavirin treatment.

• Authors: J Ambrosioni, A Mamin, A Hadengue, M Bernimoulin, K Samii, C Landelle, F Negro, L Kaiser
• Journal: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases (Clin Microbiol Infect) Vol. 20 Issue 10 Pg. O718-20 (Oct 2014) ISSN: 1469-0691 [Electronic] England
• PMID: 24476456 (Publication Type: Journal Article)
• Copyright: © 2014 The Authors Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectious Diseases.

Chemical References

• Antibodies, Monoclonal, Humanized
• Antiviral Agents
• Alemtuzumab
• Ribavirin

Topics

• Alemtuzumab
• Antibodies, Monoclonal, Humanized (administration & dosage)
• Antiviral Agents (administration & dosage)
• Diarrhea (blood, drug therapy, immunology, virology)
• Drug Therapy, Combination
• Feces (virology)
• Female
• Hepatitis E (blood, drug therapy, virology)
• Hepatitis E virus (drug effects, genetics)
• Humans
• Immunocompromised Host
• Middle Aged
• Prospective Studies
• Retrospective Studies
• Ribavirin (administration & dosage)
• Treatment Outcome
• Viral Load